That's great thanks Ken. This should not come as any surprise to...

That's great thanks Ken. This should not come as any surprise to anyone though. The ROW upfront over inflates the previous years earnings and it would have taken sales north of $500 million in 2024 to trigger a similar payment and it should in no way be seen as a failure to not get there that quickly. Sale of the PRV would obviously help but for Neuren to really soar it's all about 2591. If we hit on three or four of the Phase 2s the interest will likely be enormous and Daybue, with only 10-15% ownership still with Neuren, is not so important.

This next couple of months could be a grind. The focus will really be on Acadia to show their claim of short term seasonality is genuine and to hit the mid to upper range of the latest Q1 forecast and predicting decent growth for Q2. This will come out just as the hype around the next Phase 2 for Pitt Hopkins result starts to build so will be interesting where that puts the SP. At this point everyone should be firm on their best and worst case scenarios but until then I can't imagine what could help resurrect things except perhaps the PRV sale ??